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Background: Poly (ADP-ribose) polymerase-1 (PARP-1) is a key enzyme involved in the repair of radiation-induced
single-strand DNA breaks. PARP inhibitors such as olaparib (KU-0059436, AZD-2281) enhance tumor sensitivity to
radiation and to topoisomerase I inhibitors like camptothecin (CPT). Olaparib is an orally bioavailable inhibitor of
PARP-1 and PARP-2 that has been tested in multiple clinical trials. The purpose of this study was to investigate the
characteristics of the sensitizing effect of olaparib for radiation and CPT in order to support clinical application of
this agent.
Methods: DLD-1 cells (a human colorectal cancer cell line) and H1299 cells (a non-small cell lung cancer cell line)
with differences of p53 gene status were used. The survival of these cells was determined by clonogenic assay after
treatment with drugs and X-ray irradiation. The γH2AX focus formation assay was performed to examine the
influence of olaparib on induction and repair of double-stranded DNA breaks after exposure to radiation or CPT.
Results: A radiosensitizing effect of olaparib was seen even at 0.01 μM. Its radiosensitizing effect after exposure for
2 h was similar to that after 24 h. H1299 cells with depletion or mutation of p53 were more radioresistant than
H1299 cells with wild-type p53. However, similar enhancement of radiosensitization by olaparib was observed with
all of the tested cell lines regardless of the p53 status. Olaparib also sensitized cells to CPT. This sensitizing effect
was seen at low concentrations of olaparib such as 0.01 μM, and its sensitizing effect was the same at both 0.01 μM
and 1 μM. The combination of olaparib and CPT had a stronger radiosensitizing effect. The results of the γH2AX
focus assay corresponded with the clonogenic assay findings.
Conclusion: Olaparib enhanced sensitivity to radiation and CPT at low concentrations and after relatively short
exposure times such as 2 h. The radiosensitizing effect of olaprib was not dependent on the p53 status of tumor
cells. These characteristics could be advantageous for clinical radiotherapy since tumor cells may be exposed to low
concentrations of olaparib and/or may have different levels of p53 mutation. The combination of olaparib and CPT
had a stronger radiosensitizing effect, indicating that combining a PARP inihibitor with a topoiomerase I inhibitor
could be promising for clinical radiosensitization.
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DNA is the principal target for the biologic effects of radi-
ation. For radiotherapy, this comprises single strand breaks
(SSB) and double-strand breaks (DSB) [1]. SSB are not dir-
ectly cytotoxic but during DNA replication may generate
potentially lethal DSB by collapse of stalled replication forks* Correspondence: sakatako@sapmed.ac.jp
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reproduction in any medium, provided the orig[2]. Radiation-induced SSB are primarily repaired by base
excision repair [3], of which poly (ADP-ribose) polymerase-
1 (PARP-1) is a key component. PARP-1 binds to SSB, acti-
vating poly ADP-ribosylation of itself and other proteins,
triggering recruitment of repair factors and release of
PARP-1 from the damaged site [4]. PARP inhibitors inhibit
SSB repair and the unrepaired SSB generate collapsed repli-
cation forks which give rise to potentially lethal DSB, lead-
ing to radiosensitization [5]. Topoisomerase I poisons such
as camptothecin (CPT) exert their cytotoxic effects bytd. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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isomerase I. This enzyme plays a vital role in facilitating
unwinding of the DNA double helix during DNA replica-
tion to relieve torsional strain. The mechanism involves
temporary insertion of DNA breaks to allow unwinding,
and an intermediate DNA/protein structure termed the
‘cleavable complex’ is generated. Topoisomerase I poisons
stabilize the cleavable complex and extend the lifetime of
the associated DNA strand breaks. PARP-1 is involved in
the resolution of these DNA breaks, so inhibition of PARP
activity increases the yield of unrepaired DNA damage and
consequent cell death [6].
Olaparib (KU-0059436, AZD-2281) is an orally bio-
available inhibitor of PARP-1 and PARP-2 and a phase 1
trial using olaparib has been reported [7]. The purpose
of this study was to examine characteristics of sensitizing
effects of olaparib to radiation and a topoisomerase I in-
hibitor, CPT for clinical application of olaparib.
We found that olaparib sensitized cells to radiation and
also CPT, even at low concentrations such as 0.01 μM. The
radiosensitizing effect of olaparib at exposure for 2 h was
similar as for 24 h. These characteristics can be advanta-
geous in radiotherapy since tumor cells may have low con-
centrations of olaparib due to the limited ability of drugs to
penetrate tumor tissue. We also examined the radiosensitiz-
ing effects of the combined use of olaparib and CPT.
Methods
[Drugs, cells and cell culture]
Olaparib was obtained from JS Research Chemicals
Trading (Germany). CPT was obtained from Sigma
Chemical Company. DLD-1 is a human colorectal
carcinoma cell line. H1299 is a p53-null non-small lung
carcinoma cell line. H1299 cells were transfected with
pCMV-Bam-Neo vector (neo) alone (as a control) and
with wild-type p53 (wt) or mutated p53 gene [8,9].
H1299/mp143 (m143), H1299/mp175 (m175), and
H1299/mp248 (m248) were made with transfection of
mutated p53 gene into codon 143, 175, 248 of H1299
cells, respectively. To determine whether p53 mRNA and
the protein were stably expressed in these transfectants,
we analyzed the reverse transcriptase-polymerase chain
reaction restriction fragment length polymorphism on the
sequence of transfected codon of the p53 gene for the
mRNA. We also performed Western blot analysis for the
protein. H1299 (wt, m248, m175, m143, neo) cells were
cultured in MEM medium supplemented with 10% fetal
calf serum. DLD-1 was cultured in RPMI-1640 medium
supplemented with 10% fetal calf serum. All these cell
lines were cultured at 37°C.
[Cell culture and clonogenic assay]
The survival of these cells after various treatments such as
drug treatment and X-ray irradiation was determined astheir colony-forming ability. The time between plating
cells and treatments such as radiation and/or drug expos-
ure was 24 h. Experiments were repeated three times.
Mean values and standard error of the mean were
expressed. We tested the significance at the p< 0.05
for our observations. The X-ray dose-survival curves
were fitted to the linear quadratic equation, survival
fraction = exp (−αD-βD2), where D is the X-ray dose. D37,
the X-ray dose giving 37% survival was calculated from
the fitted linear quadratic equation. Enhancement ratio
was calculated as the D37 of untreated cells divided by that
of treated cells. Since CPT have the cell killing effects, we
excluded their cell killing effects in the calculation of en-
hancement ratio. We made the hypothetical survival curve
in which the value of survival fraction was 1 at 0 Gy in the
combined treatment of CPT and radiation.[γH2AX focus assay]
Mouse monoclonal anti-γH2AX (Upstate, NY, USA) anti-
body and rabbit polyclonal anti- Rad51 (Oncogene, CA,
USA) antibody were used. DLD-1 cells were exposed to
olaparib (1 μM) for 8 h and/or CPT (0.01 μM) for 6 h.
Since CPT has the cell killing effect, we used the shorter
exposure time in CPT than olaparib. When cells were
irradiated, 4 Gy of radiation was performed after 4 h ex-
posure of olaparib and/or 2 h exposure of CPT. Then,
cells were applied on slide glass at 24 h after irradiation.
Cells diluted to appropriate numbers were grown on a
glass slide and fixed with cold methanol for 20 min, rinsed
with cold acetone for 10 seconds, and then air-dried.
Above mentioned antibodies to γH2AX or Rad51 were
used as the primary antibody. Alexa-546-conjugated anti-
mouse IgG (Molecular Probes) were used for visualization
of γH2AX and Rad51. Slides were mounted with antifade
reagent (Mounting medium, DAKO). Foci were observed
with an Olympus fluorescent microscope under 10 × 100
oil immersion. For quantification of foci, clear and easily
distinguished dots of certain brightness were counted as
positive foci. The number of foci was counted in 100 cells
of sample each time point by visual inspection and average
number of foci per cell was calculated. Cells that had 5 or
more of Rad51 were considered as Rad51 positive.[Flowcytometry]
For estimation of the distribution of cells in different phases
of the cell cycle, FACS-analysis of cells stained with propi-
dium iodide (PI) was performed. Harvested cells were fixed
in 70% of ethanol and stored at 4°C until analysis. Fixed
cells were washed once in PBS, incubated with PBS supple-
mented with RNase A (0.25 mg/ml) for 30 min at 37°C and
stained in a PI-containing solution (50 μg PI/ml in PBS) for
10 min at 4°C. The cells were analyzed on a flowcytometer
(FACS Calibur, Becton Dickinson, USA).
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[Radiosensitizing effect of olaparib at various exposure
times and concentrations]
Figure 1a demonstrates the relationship between the
concentration of olaparib and its radiosensitizing ef-
fect. The surviving fraction was significantly reduced
after exposure to 0.01 μM olaparib (p< 0.05) compared
with the control (radiation alone), indicating that this
agent had a radiosensitizing effect even at low concentra-
tions. The radiosensitizing effect increased in a concentra-
tion-dependent manner. Figure 1b demonstrates theFigure 1 a. The relationship between concentrations of olaparib and
concentrations of olaparib for 1 h before radiation and 24 h after radiation
olaparib and radiosensitizing effects. DLD-1 cells were treated with 1 μM
c. Clonogenic cell survival assay of H1299 cells with various status of
mutated p53 gene into codon 143, 175, 248 of H1299 cells, respectively. “C
radiation and olaparib. Cells were treated with 1 μM of olaparib for 1 h befrelationship between the exposure time and the radiosen-
sitizing effect of olaparib. A radiosensitizing effect was
seen after only 2 h of exposure, and it was similar to the
effect after 24 h of exposure.
Additional file 1 shows the relationship between the ola-
parib concentration and its radiosensitizing effect on
DLD-1 cells. These cells were treated with 4 Gy of radi-
ation and were exposed to various concentrations of ola-
parib for 1 h before irradiation and 24 h after irradiation.
Additional file 2 shows the relationship between the ola-
parib exposure time and its radiosensitizing effect onradiosensitizing effects. DLD-1 cells were treated with various
. b. The relationship between exposure time (1 h or 24 h) of
of olaparib for 1 h before radiation and 1 h or 23 h after radiation.
p53 gene. m143, m175, and m248 were made with transfection of
ontrol”: treated with radiation alone; “Olaparib (+)”:treated with
ore radiation and 2 h after radiation.
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Additional file 2 correspond with those shown in Figure 1a
and 1b. Cells were treated with 4 Gy of radiation and were
exposed to 1 μM olaparib for 1 h before irradiation and
various times after irradiation. In these experiments, a ra-
diation dose of 4 Gy was used since it killed more cells
than 2 Gy, and the difference between various treatments
was clearer at 4 Gy.
Olaparib did not decrease plating efficiency at any of
the exposure times or concentrations examined in this
study.
[Radiosensitizing effect of olaparib on human cancer cells
with different p53 statuses]
We examined whether the p53 status of tumor cells
influenced the enhancement of radiosensitivity by ola-
parib. To assess the influence of p53 status, we used five
human lung cancer cell lines with identical genotypes
except for p53 (wt, m143, m175, m248, and neo) and
found that wt cells were significantly more radiosensitive
than m143 and neo cells (p< 0.01). Conversely, m143
cells were significantly more radioresistant than m248
and wt cells (p< 0.01). These results indicated that the
p53 status influenced the radiosensitivity of H1299 cell
lines.
Olaparib enhanced the radiosensitivity of all tumor
cell lines examined, especially at higher radiation doses
(Figure 1c). Table 1 shows the values of α and β in the
linear quadratic equation for calculating the surviving
fraction, i.e., surviving fraction = exp (−αD-βD2). Similar
enhancement of radiosensitization was observed with all
cell lines tested regardless of the p53 status. Exposure to
olaparib alone (1 μM, 3 h) did not affect the plating effi-
ciency of any cell line examined in this study.
[Sensitization to CPT by olaparib]
In order to examine the influence of olaparib on the sensi-
tivity of DLD-1 cells to the topoisomerase I inhibitor CPT,
we performed a clonogenic cell survival assay. Figure 2aTable 1 Radiation enhancement ratio by olaparib
α β enhancement ratio
wt Control 0.27 ±0.082 0.053 ±0.016 1.1
Olaparib(+) 0.28 ±0.022 0.065 ±0.002
neo Control 0.19 ±0.015 0.049 ±0.002 1.1
Olaparib(+) 0.22 ±0.039 0.059 ±0.008
m143 Control 0.11 ±0.030 0.047 ±0.005 1.2
Olaparib(+) 0.13 ±0.052 0.060 ±0.009
m175 Control 0.22 ±0.086 0.048 ±0.015 1.2
Olaparib(+) 0.29 ±0.076 0.051 ±0.012
m248 Control 0.21 ±0.094 0.054 ±0.013 1.1
Olaparib(+) 0.26 ±0.027 0.053 ±0.005demonstrates that olaparib sensitized the cells to CPT.
This effect was seen even at low concentrations of CPT,
such as 0.005 μM, and it was maximal around 0.01 or
0.015 μM.
We also examined the influence of the concentration
of olaparib on its sensitizing effect, especially in regard
to low concentrations (Figure 2b). A sensitizing effect
was evident at only 0.01 μM and the strength of the sen-
sitizing effect was the same at both 0.05 μM and 1 μM.
[Radiosensitization with olaparib plus CPT]
Figure 3a shows the surviving fraction of DLD-1 cells
after irradiation combined with exposure to olaparib
and/or CPT. Since CPT had a cytotoxic effect, the sur-
viving fraction was less than 1 at 0 Gy. Compared with
radiation alone, radiation combined with olaparib or
CPT significantly reduced the surviving fraction of DLD-
1 cells (p< 0.01). The greatest reduction of the surviving
fraction was achieved by the combination of 1 μM of
olaparib and CPT (p< 0.001).
As shown in Figure 3b, the surviving fraction of cells
exposed to CPT at 0 Gy of irradiation has been adjusted
to 1. It can be seen that the combination of olaparib and
CPT had the strongest effect since olaparib increased
sensitivity to both radiation and CPT. The enhancement
ratio (D37) for 0.1 μM olaparib and CPT was 1.37, while
that for 1 μM olaparib and CPT was 1.45. In addition,
the enhancement ratio (D37) for 1 μM olaparib alone
was 1.20 and that for CPT alone was 1.33.
[γH2AX focus formation assay after irradiation or CPT]
In order to examine the relationship between olaparib-
induced sensitization to radiation or CPT and the induc-
tion of double-stranded DNA breaks (DSB), we counted
residual γH2AX foci at 24 h after irradiation and 20 h
after treatment with olaparib and/or CPT (Figure 4). We
also analyzed γH2AX foci in relation to the existence of
Rad51 foci. Induction of Rad51 by irradiation is cell-
cycle dependent, since it is preferentially formed in the S
and G2/M phases [10]. Thus, the results of the γH2AX
focus assay can be evaluated by taking into consideration
the influence of the cell cycle.
Figure 4a shows the γH2AX and Rad51 foci in un-
treated DLD-1 cells, cells treated with irradiation
(IR), and cells treated with CPT. Figure 4b presents
the results for cells with Rad51 foci. There was no
significant difference between the control cells (Ola-,
CPT-, IR-) and cells treated with olaparib (Ola+,
CPT-, IR-), suggesting that olaparib alone did not in-
duce DSB. Cells treated with radiation (Ola-, CPT-,
IR+) had significantly more foci than control cells
(Ola-, CPT-, IR-) as did cells treated with CPT (Ola-,
CPT+, IR-), indicating that radiation or CPT induced
DSB. Cells exposed to radiation combined with
Figure 2 a. The effect of olaparib on CPT toxicity. DLD-1 cells were treated with 1 μM of olaparib and various cocentrations of CPT for 6 h.
Values shown are the mean ± standard error of the mean. b. The relationship between concentrations of olaparib and sensitizing effects to
CPT in DLD-1 cells. Cells were treated with 0.01 μM of CPT and various concentrations of olaparib for 6 h. Values shown are the mean ±
standard error of the mean.
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foci than cells treated with radiation alone (Ola-,
CPT-, IR+). In addition, cells exposed to CPT com-
bined with olaparib (Ola+, CPT+, IR-) showed sig-
nificantly more foci than cells treated with CPT
alone (Ola-, CPT+, IR-), revealing that olaparib
enhanced the induction of DSB by radiation or CPT.
Cells exposed to radiation combined with olaparib
(Ola+, CPT-, IR+) had a similar number of foci as
cells exposed to radiation combined with CPT (Ola-,
CPT+, IR+), showing that olaparib and CPT caused simi-
lar enhancement of the induction of DSB by radiation.
Cells exposed to radiation combined with olaparib and
CPT (Ola+, CPT+, IR+) had the most foci among all of
the treatment groups.Figure 4c presents the results for cells without
Rad51 foci. The findings are similar to those shown
in Figure 4b. However, the enhancement of radi-
ation-induced DSB by olaparib and/or CPT was less
marked in cells without Rad51 foci than in cells with
Rad51 foci. There was no significant difference be-
tween radiation combined with olaparib (Ola+, CPT-,
IR+) and radiation alone (Ola-, CPT-, IR+) in cells
without Rad51 foci.
[Effects of olaparib, CPT and radiation on the cell cycle]
Figure 4d shows the cell cycle after the same treat-
ments as Figure 4b and c. There was no difference
between the control cells (Ola-, CPT-, IR-) and cells
treated with olaparib (Ola+, CPT-, IR-), indicating
Figure 3 a. Cell survivals with radiation combined with olaparib and/or CPT. DLD-1 cells were treated with 0.1 or 1 μM of olaparib and/or
0.01 μM of CPT for 4 h before irradiation and for 2 h after radiation. b. Radiosensitization with olaparib and/or CPT. Figure 3b was made by
modifying Figure 3a. The survival fraction of CPT at 0 Gy in Figure 3a was corrected to 1.
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butions. Cells treated with radiation (Ola-, CPT-, IR+) or
CPT (Ola-, CPT+, IR-) tended to have more S phase cells
than the control cells (Ola-, CPT-, IR-). Radiation and ola-
parib (Ola+, CPT-, IR+) had the similar cell cycle distribu-
tion to radiation alone (Ola-, CPT-, IR+). In contrast, cells
treated with CPT and olaparib (Ola+, CPT+, IR-) tended
to have reduced S phase cells, compared with CPT alone
(Ola-, CPT+, IR-). Cells treated with olaparib, CPT and ra-
diation (Ola+, CPT+, IR+) had increased G2/M phase cells
and reduced S phase cells, compared with the other
treatments.Discussion
PARP inhibitors such as olaparib increase sensitivity to
radiation and to topoisomerase I inhibitors such as CPT
[4]. The concentration of olaparib tested in previous
studies was 0.5 or 1 μM [5,11]. In a clinical study, the
plasma concentration of olaparib reached 11.5 μM
(5 μg/ml) after oral administration of 100 or 200 mg,
which are doses that do not cause dose-limiting toxicity
[7]. The present findings support the clinical usefulness
of olaparib at oral doses of 100 to 200 mg. However, the
ability of drugs to penetrate tumor tissue in vivo is often
limited, so that some tumor cells may not be exposed
Figure 4 γH2AX foci at 24 hours after irradiation and cell cycle distribution. DLD-1 cells were treated with 4 Gy of radiation and/or 1 μM of
olaparib for 8 h and/or 10nM of CPT for 6 h. (a) Foci of γH2AX and Rad51 in DLD-1 cells treated with various combinations of olaparib, CPT, or
irradiation (IR). DAPI(4',6-diamidino-2-phenylindole) was used to stain nucleus. Ola(+): with olaparib. IR(−): without irradiation. (b) Results of cells
that were positive for Rad51 foci. (c) Results of cells that were negative for Rad51 foci. (d) Cell cycle distributions.
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sible that tumor cells may be exposed to much lower
olaparib concentrations than 0.5 or 1 μM. For this
reason, we examined the sensitizing effect of olaparib
for radiation and CPT at very low concentrations.
Figure 1a demonstrates the relationship between the
olaparib concentration and its radiosensitizing effect on
DLD-1 cells. Although the radiosensitizing effect of ola-
parib showed a concentration-dependent increase, low
concentrations (such as 0.01 μM) still had a radiosensi-
tizing effect, indicating that effective radiosensitization
achieved even for tumor cells exposed to low concentra-
tions of this agent.We also examined the relationship between the expos-
ure time and the radiosensitizing effect of olaparib.
Figure 1b demonstrates that the radiosensitizing effect of
olaparib after exposure for 2 h was similar to that at 24 h,
demonstrating that effective radiosensitization could be
achieved even for tumor cells with a short exposure time.
Olaparib enhances radiosensitivity by inhibiting the repair
of SSB. Unrepaired SSB lead to collapse of replication
forks that give rise to potentially lethal DSB, leading to
radiosensitization [5]. Thus, SSB are converted to DSB
during replication after exposure to olaparib [13]. Longer
incubation times than 2 h after irradiation might be
required to convert SSB to DSB since the cell cycle of
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that 2 h of incubation with olaparib after irradiation is suf-
ficient for radiosensitization and that exposure to this
agent throughout the entire period of SSB repair is not ne-
cessary to enhance the generation of DSB.
In order to test the potential clinical value of olaparib,
we also examined whether the p53 status of tumor cells
influenced the enhancement of radiosensitization using
five human lung cancer cell lines with identical geno-
types except for p53 (wt, m143, m175, m248, and neo).
We found that H1299 cells with depletion or mutation
of p53 were more radioresistant than H1299 cells with
wild-type p53, showing that p53 status influenced the
radiosensitivity of these cell lines. There have been con-
flicting reports concerning the relationship between p53
status and radiosensitivity. Some authors have reported
that p53 gene mutation decreases radiosensitivity [14],
while others have reported an increase of radiosensitivity
[15] or no correlation with radiosensitivity [16]. Because
p53 regulates multiple aspects of the cell cycle, DNA re-
pair, and apoptosis after irradiation [17], this protein not
only determines cell death but also cell survival. Accord-
ingly, cells with various p53 statuses could be more
radiosensitive or radioresistant [18]. In the present study,
the surviving fraction was reduced by exposure to ola-
parib for all of the cell lines tested with various p53
statuses. Enhancement of radiosensitization was similar
for all of the cell lines regardless of p53 status (Table 1),
indicating that the radiosensitizing effect of olaparib is
independent of p53.
Next, we investigated the effect of olaparib on sensitiv-
ity to CPT. Figure 2a shows the relationship between the
olaparib concentration and its CPT-sensitizing effect.
Olaparib sensitized cells to the cytotoxic effect of CPT, even
at a CPT concentration of only 0.005 μM. The combination
of olaparib with CPT significantly reduced the surviving
fraction over the range of CPT concentrations from 0.005
to 0.02 μM. We also examined the relationship between the
sensitizing effect of olaparib and its concentration, espe-
cially at low concentrations (Figure 2b). A sensitizing effect
was still apparent at a concentration of 0.01 μM and the ef-
fect seen at this level was similar to that obtained at 1 μM.
We then investigated the combined effects of olaparib,
CPT, and radiation. Figure 3a displays the surviving frac-
tion of DLD-1 cells after treatment with olaparib and/or
CPT. The combination of radiation with olaparib or
CPT significantly increased the lethal effect of radiation
(p< 0.01), except when olaparib was combined with
2 Gy. The cytotoxic effect of olaparib, CPT, and radi-
ation all together was much greater than that of radi-
ation alone.
In order to compare the radiosensitizing effect of CPT
with that of olaparib, we adjusted the surviving fraction at
0 Gy to 1 in Figure 3b, since CPT itself had a cytotoxiceffect. Then we assessed the radiosensitivity of DLD-1
cells after treatment with olaparib or CPT. The radio-
sensitizing effect of 1 μM olaparib was similar to that
of CPT at 4 Gy and greater than that of CPT at 6 and
8 Gy (p< 0.01). Since olaparib increased sensitivity to
both radiation and CPT, the combination of olaparib and
CPT had the strongest radiosensitizing effect. The en-
hancement ratio (D37) of olaparib plus CPT was larger
than that for either olaparib alone or CPT alone. Thus,
combination therapy with PARP inhibitors and topoisom-
erase I inhibitors may be a promising strategy for enhan-
cing the effects of radiotherapy.
After DSB are induced by irradiation or cytotoxic drugs,
H2AX is rapidly phosphorylated and there is always a con-
stant number or percentage of γH2AX formed per DSB.
Therefore, γH2AX is a sensitive and early indicator of DSB
in vitro and in vivo [19]. Furthermore, residual γH2AX at
24 h after irradiation can be used to assess the radiosensi-
tivity of cells or their ability to recover from damage and
the efficiency of the cellular repair process [20]. Accord-
ingly, we investigated residual γH2AX foci after exposure of
cells to radiation, olaparib, and CPT. Olaparib alone did
not increase γH2AX foci, while radiation or CPT did so.
Radiation combined with olaparib and CPT produced the
most foci among all of the treatment groups. These findings
agreed with the results of clonogenic assays, suggesting that
the sensitizing effect of olaparib for radiation or CPT is
related to induction of DSB or to inhibiting the repair of
DSB. We also used radiation-induced Rad51 foci to investi-
gate the cell cycle dependence of γH2AX focus formation
after various treatments. We found that enhancement of
radiation-induced DSB by olaparib and CPT was greater in
cells with Rad51 foci than in cells without Rad51 foci, indi-
cating that olaparib had a stronger effect on the induction
of DSB by radiation or CPT in the S and G2/M phases than
in the G1 phase.
Figure 4d shows the cell cycle after the treatments
with olaparib, CPT, or radiation.
Olaparib alone did not change cell cycle distributions.
Cells treated with radiation or CPT had more S phase cells
than the control cells, corresponding to that radiation [21]
or CPT [22] arrests or delays cell cycle progression during
the S phase. Cells treated with CPT and olaparib had less
S phase cells than CPT alone. This might suggest that ola-
parib enhances the S phase specific cell killing effect of
CPT [23]. The combination of olaparib, CPT and radiation
reduced S phase and increased G2/M phase. This effect
might result from S phase specific cell killing with CPT
and G2/M arrest with radiation.
Conclusion
Olaparib enhanced the sensitivity of radiation and CPT,
even at low concentrations, such as 0.01 μM. The radiosen-
sitizing effects of olaparib at exposure for 2 h had the
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not depend on p53 status. These characteristics can be ad-
vantageous in clinical radiotherapy since tumor cells may
have low concentrations of olaparib and/or p53 mutation.
The combination of olaparib and CPT had the good radio-
sensitizing effects, indicating that the combination of PARP
inhibitor and topoiomerase I inhibitor can be promising as
a method of clinical radiosensitization.
Additional files
Additional file 1: The relationship between concentrations of
olaparib and radiosensitizing effects. DLD-1 cells were treated with
4 Gy of radiation and various concentrations of olaparib for 1 h before
radiation and 24 h after radiation.
Additional file 2: The relationship between exposure time of
olaparib and radiosensitizing effects. DLD-1 cells were treated with
4 Gy of radiation and 1 μM of olaparib for 1 h before radiation and
various times after radiation.
Competing interest
The authors declare that they have no competing interests.
Authors’ contributions
KM performed experiments and drafted the manuscript. KS conceived of the
study and drafted the manuscript. MS performed γ-H2AX assay. YM
participated importantly in the conception of the study and helped to draft
the manuscript. HM and AT made H1299 cells with various p53 status and
analyzed these characteristics of cells. MH participated importantly in the
conception and design and helped to draft the manuscript. All authors read
and approved the final manuscript.
Acknowledgments
The research were supported in part by a Grant-in Aid for Scientific Research
from the Ministry of Education, Culture, Sports, Science and Technology,
Japan and by a grant from program for developing the supporting system
for upgrading the education and research in Sapporo Medical University.
Author details
1Department of Radiology, Sapporo Medical University, School of Medicine,
S1W16, Chuo-Ku, Sapporo 060-8543, Japan. 2Tokyo Institute of Technology,
Research Laboratory for Nuclear Reactors, N1-30 2-12-1 Ookayama, Meguro-
ku, Tokyo 152-8550, Japan. 3Department of Oncology, Biomedical Imaging
Research Center, University of Fukui, Eiheiji-cho, Fukui 910-1193, Japan.
4Advanced Scientific Research Leaders Development Unit, Gunma University,
3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan.
Received: 17 October 2011 Accepted: 2 April 2012
Published: 23 April 2012
References
1. Hall EJ: DNA strand breaks and chromosomal aberrations. In Radiobiology
for the radiologist, ed. 6th edition. Edited by Hall EJ, Giaccia AM. Philadelphia:
Lippincott Williams & Wilkins; 2006:16–29.
2. Saleh-Gohari N, Bryant HE, Schultz N, Parker KM, Cassel T, Helleday T:
Spontaneous homologous recombination is induced by collapsed
replication forks that are caused by ebdogenous DNA single-strand
breaks. Mol Cell Biol 2005, 25(16):7158–7169.
3. Caldecott KW: Protein-protein inetractions during mammalian DNA
single-strand break repair. Biochem Soc Trans 2003, 31:247–251.
4. Chalmers AJ: The potential role and application of PARP inhibitors in
cancer treatment. Brit Med Bull 2009, 89:23–40.
5. Dungey FA, Loser DA, Chalmers AJ: Replication-dependent radiosensitization
of human glioma cells by inhibition of poly (ADP-ribose) polymerase:
mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 2008,
72(4):1188–1197.6. Smith LM, Willmore E, Austin CA, Curtin NJ: The novel poly (ADP-ribose)
polymerase inhibitor, AG14361, sensitizes celss to topoisomerase I
poisons by increasing the persistence of DNA strand breaks. Clin Cancer
Res 2005, 11(23):8449–8457.
7. Fong PC, Boss DS, Timothy A, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P,
Swaisland H, Lau A, O’Connor MJ, Ashworth A, Carmichael J, Kaye SB,
Schellens JHM, de Bono JS: inhibition of poly (ADP-ribose) polymerase in
tumors from BRCA mutation carriers. N Engl J Med 2009, 361(2):123–134.
8. Jin Z-H, Matsumoto H, Hayashi S, Hatashita M, Ohtsubo T, Shioura H, Kitai R,
Kano E: p53-independent thermosensitization by mitomycin c in human
non-small-cell cancer cells. Int J Radiat Oncol Biol Phys 2004, 59:852–860.
9. Kawashima D, Soga M, Takeuchi R, Matsumoto H, Ohtsuka K:
Molecular caperone inducers facilitate the functional restoration of
temperature-sensitive mutant p53 protein. Thermal Med 2010,
26:1–17.
10. Yuan SF, Chang H, Lee EY: Ionizing radiation-induced Rad51 nuclear focus
formation is cell cycle-regulated and defective in both ATM-/- and
c-Abl-/- cells. Mutat Res 2003, 525:85–92.
11. Loser DA, Shibata A, Shibata AK, Woodbine LJ, Jeggo PA, Chalmers AJ:
Sensitization to radiation and alkylating agents by inhibitors of poly
(ADP-ribose) polymerase is enhanced incells deficient in DNA
double-strand break repair. Mol Cacncer ther 2010, 9(6):1775–1787.
12. Tredan O, Galmarini CM, Patel K, Tannock IF: Drug resistamce and the solid
tumor microenvironment. J Natl Cancer Inst 2007, 99:1441–1454.
13. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S,
Meuth M, Curtin NJ, Helleday T: Specific killing of BRCA2-deficient
tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005,
434:913–917.
14. Sinclair WK: The combined effects of hydroxyurea and x-rays on Chinese
hamster cells in vitro. Cancer Res 1968, 28:198–206.
15. Brachman DG, Beckett M, Graves D, Haraf D, Vokes E, Weichselbaum RR:
p53 mutation does not correlate with radiosensitivity in 24 head and
neck cancer cell lines. Cancer Res 1993, 53(16):3667–3669.
16. Slichenmyer WJ, Nelson WG, Slebos RJ, Kastan MB: Loss of a p53-
associated G1 checkpoint does not decrease cell survival following DNA
damage. Cancer Res 1993, 53(18):4164–4168.
17. Hall EJ: Repair of radiation damage and the dose-rate effect. In
Radiobiology for the radiologist, ed. 6th edition. Edited by Hall EJ, Giaccia AM.
Philadelphia: Lippincott Williams & Wilkins; 2006:60–84.
18. Takahashi A, Matsumoto H, Yuki K, Yasumoto J, Kajiwara A, Aoki M,
Furusawa Y, Ohnishi K, Ohnishi T: High-LET radiation enhanced apoptosis
but not necrosis regardless of p53 status. Int J Radiat Oncol Biol Phys 2004,
60(2):591–597.
19. Rogakou EP, Nieves-Neira W, Boon C, Pommier Y, Bonner WM: Initiation of
DNA fragmentation during apoptosis induces phosphorylation of H2AX
histone at serine 139. J Biol Chem 2000, 275:9390–9395.
20. Klokov D, MacPhail SM, Banath JP, Byrne JP, Olove PL: Phosphorylated
histone H2AX in trlation to cell survival in tumor cells and xenografts
exposed to single and fractionated doses of X-rays. Radiother Oncol 2006,
80:223–229.
21. Guo CY, D’Anna JA, Larner JM: The radiation-induced S-phase checkpoint
is independent of CDKN1A. Radiat Res 1999, 151:125–132.
22. Shao R-G, Cao C-X, Shimizu T, O’Connor PM, Kohn KW, Pommier Y:
Abrogation of an S-phase checkpoint and potentiation of camptothecin
cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell
lines, possibly influenced by p53 function. Cancer Res 1997, 57:4029–4035.
23. Hsiang Y-H, Lihou MG, Liu LF: Arrest of replication forks by drug-stabilized
topoisomerase I-DNA cleavable complexes as a mechanism of cell killing
by camptothecin. Cancer Res 1989, 49:5077–5082.
doi:10.1186/1748-717X-7-62
Cite this article as: Miura et al.: The combination of olaparib and
camptothecin for effective radiosensitization. Radiation Oncology 2012
7:62.
